- Keros Therapeutics press release ( NASDAQ: KROS ): Q3 GAAP EPS of -$0.92 beats by $0.31 .
- Keros’ cash and cash equivalents as of September 30, 2022 was $239.4 million compared to $230.0 million as of December 31, 2021.
- The company expects that the cash and cash equivalents it had on hand at September 30, 2022, together with the net proceeds from the ATM offering through October 31, 2022, will enable Keros to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.
For further details see:
Keros Therapeutics GAAP EPS of -$0.92 beats by $0.31